ORIGINAL ARTICLE
Year : 2022 | Volume
: 6 | Issue : 1 | Page : 19--22
Mineral bone disorders in hemodialysis patients in the West of Libya
Khairi Ayad1, Badreddin Shaibani2, Zaynab Rahouma1, Yousef AL-Adawi2, Fatma Malool3, Amina Smaida4, Samiha Shamli5, Reema Gattusa6
1 Department of Nephrology, Sabratha Teaching Hospital, Sabratha, Libya
2 Department of Hemodialysis, AZ Zawiyah Kidney Hospital, Az-zawiyah, Libya
3 Department of Dialysis, Surman General Hospital, Surman, Libya
4 Department of Hemodialysis, Agelat Hospital, Al Agelat, Libya
5 Department of Hemodialysis, Algmail Hospital, Al Gmail, Libya
6 Department of Hemodialysis, Hemodialysis Unit, Zawara Hospital, Zawara, Libya
Correspondence Address:
Dr. Khairi Ayad
Department of Nephrology, Sabratha Teaching Hospital, Sabratha
Libya
Background and Objectives: Chronic kidney disease (CKD) is affecting 5%–10% of the world population. As kidney function declines, there is progressive deterioration in minerals homeostasis manifesting as disruption of serum and tissue concentrations of phosphorus, calcium (Ca), and parathyroid hormone (PTH). CKD-mineral bone disorder (CKD-MBD) is a systemic disorder of mineral and bone metabolism manifested by any or a combination of the following: abnormalities of Ca, phosphorus, PTH, Vitamin D metabolism, abnormalities of bone turnover, and vascular or soft-tissue calcification, associated with fractures, cardiovascular disease, and mortality in CKD patients. The study aims to identify the prevalence and pattern of CKD-MBD among hemodialysis patients in the west of Libya. Patients and Methods: A cross-sectional study was carried out on 186 regular hemodialysis patients from five hemodialysis centers in the west of Tripoli-Libya District. All patients were investigated for complete blood count, blood sugar, serum albumin, blood urea, serum creatinine, total Ca level, serum phosphate, serum alkaline phosphatase, and serum intact PTH (iPTH) level. Results: According to the Kidney Disease Outcomes Quality (KDOQ) iPTH level guideline, 88.10% of the studied patients had metabolic bone disorders, and 39.80% showed low bone turnover. About 48.40% were high bone turnover; only 11.80% of studied patients were within the target range according to the KDOQ Initiative guidelines. About 40.36% of studied patients had low calcium levels (below 8.5 mg%), and 35.48% had high phosphorus levels (more than 5.5 mg%). About 61.10% of high bone turnover patients complain of bone pain and 50.50% complain of muscle weakness. Among low bone turnover patients, 36.48% had no symptoms, and 28.38% were complaining of both muscle weakness and bone pain. Conclusions: The prevalence of MBDs among studied patients with abnormal PTH levels is 87.6%, distributed as 39.2% in abnormal low PTH (low bone turnover), and 48.4% in abnormal high PTH (high bone turnover).
How to cite this article:
Ayad K, Shaibani B, Rahouma Z, AL-Adawi Y, Malool F, Smaida A, Shamli S, Gattusa R. Mineral bone disorders in hemodialysis patients in the West of Libya.Libyan J Med Sci 2022;6:19-22
|
How to cite this URL:
Ayad K, Shaibani B, Rahouma Z, AL-Adawi Y, Malool F, Smaida A, Shamli S, Gattusa R. Mineral bone disorders in hemodialysis patients in the West of Libya. Libyan J Med Sci [serial online] 2022 [cited 2023 Mar 30 ];6:19-22
Available from: https://www.ljmsonline.com/article.asp?issn=2588-9044;year=2022;volume=6;issue=1;spage=19;epage=22;aulast=Ayad;type=0 |
|
